So many scientific studies are making incorrect claims that a new service has sprung up to fact-check reported findings by repeating the experiments.
A year-old Palo Alto, California, company, Science Exchange, announced on Tuesday its “Reproducibility Initiative,” aimed at improving the trustworthiness of published papers. Scientists who want to validate their findings will be able to apply to the initiative, which will choose a lab to redo the study and determine whether the results match.
The project sprang from the growing realization that the scientific literature - from social psychology to basic cancer biology - is riddled with false findings and erroneous conclusions, raising questions about whether such studies can be trusted. Not only are erroneous studies a waste of money, often taxpayers’, but they also can cause companies to misspend time and resources as they try to invent drugs based on false discoveries.
Last year, Bayer Healthcare reported that its scientists could not reproduce some 75 percent of published findings in cardiovascular disease, cancer and women’s health. In March, Lee Ellis of M.D. Anderson Cancer Center and C. Glenn Begley, the former head of global cancer research at Amgen, reported that when the company’s scientists tried to replicate 53 prominent studies in basic cancer biology, hoping to build on them for drug discovery, they were able to confirm the results of only six.
The new initiative, said Begley, senior vice president of privately held biotechnology company TetraLogic, “recognizes that the problem of non-reproducibility exists and is taking the right steps to address it.”
The initiative’s 10-member board of prominent scientists will match investigators with a lab qualified to test their results, said Elizabeth Iorns, Science Exchange’s co-founder and chief executive officer. The original lab would pay the second for its work. How much depends on the experiment’s complexity and the cost of study materials, but should not exceed 20 percent of the original research study’s costs. Iorns hopes government and private funding agencies will eventually fund replication to improve the integrity of scientific literature.